Evidence map›Paper›PMID 36372666›Full record

ArticleVaccine2022

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.

Stephan Skawran, Helen Schiesser, Alexander Maurer, Thomas Sartoretti, Manuel Dittli, Cäcilia Mader, Alessandra Curioni-Fontecedro, Christoph Berger, Martin W Huellner, Michael Messerli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephan SkawranDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland. Electronic address: stephan.skawran@usz.ch.
Helen SchiesserDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Alexander MaurerDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Thomas SartorettiDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Manuel DittliDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Cäcilia MaderDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Alessandra Curioni-FontecedroUniversity of Zurich, Switzerland; Department of Medical Oncology, University Hospital Zurich, Switzerland.
Christoph BergerUniversity of Zurich, Switzerland; Division of Infectious Diseases and Children's Research Centre, University Children's Hospital Zurich, Switzerland.
Martin W HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.
Michael MesserliDepartment of Nuclear Medicine, University Hospital Zurich, Switzerland; University of Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort.

methodsHistory of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination.

resultsRate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate.

conclusionVaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.

Indexed as

COVID-19Fluorodeoxyglucose F18COVID-19 VaccinesHumansPositron Emission Tomography Computed TomographyVaccinationCOVID-19 VaccinesFluorodeoxyglucose F18CancerCOVID-19FluordeoxyglucoseOncological ImagingVaccination

Identifiers

PMID36372666
PMCPMC9637529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.